Akili Interactive adds $13 million to Series C funding pool

9 August 2018

Digital medicine company Akili Interactive Labs, an independent affiliate of the biotech company PureTech Health, has announced an additional $13 million worth of investment in its ongoing Series C funding campaign which now totals $68 million.

Participants in this latest round of investment include Digital Garage and Fearless Ventures, which join existing investors including Brooklands Capital Strategies and Bailie Gifford, alongside the investment divisions of Amgen (Nasdaq: AMGN) and Merck KGaA (MRK: DE).

"CLSA’s investments are focused on transformative ideas and technologies that have the potential to disrupt sectors and practices. Validated digital medicine is one such area, with potential to change the industry, especially in treating cognitive dysfunction," said Jonathan Slone, head of CLSA, a major Asian investment bank. "Akili is a pioneer in the field, and we’re excited to support the company’s growth."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK